Clinical trial
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
NCT00107432 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00107432 |
|---|---|
| Title | Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. |
| Official title | A Phase II Study of BAY 43-9006 (NSC #724772) in Patients With Malignant Mesothelioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 44 |
| Start date | Oct 1, 2004 |
| Primary completion | Jun 1, 2007 |
| First posted | Apr 6, 2005 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: